Abstract
We read with interest the editorial by Sparacino-Watkins et al1 that accompanied our recent article2 demonstrating the beneficial effects of dietary inorganic nitrate supplementation in experimental models of pulmonary hypertension (PH). The editorial provides a timely overview of the scientific rationale for exploiting the recently characterized nitrate-nitrite-nitric oxide pathway in PH and other cardiovascular disorders. We agree with the authors that a therapeutic approach based on this pathway represents an exciting new avenue for a debilitating disease with very poor outcome. However, we wish to clarify an apparent misunderstanding regarding the dose required for efficacy in humans. Sparacino-Watkins et al suggest that the concentrations …
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
